STING1 and cancer: Novel strategies to target innate immunity in cancer therapy have emerged in recent years, including the DNA sensing cGAS/STING pathway [8, 9], Toll-like receptors (TLRs) [10], nucleotide-binding oligomerization domain-like receptors NLRP3, and the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) [11, 12].